In the pharma industry time is money and there is nowhere more than in the processes of research and production of medicines.
A strategic way to reduce delays is to collaborate with a pharma support specialised Contract Development and Manufacturing Organization (CDMO).
In these collaborations, the CDMO’s expertise and infrastructure are brought to bear to optimise complex processes, which can help to eliminate inefficiencies at critical points.
Below we will analyse three key ways in which CDMO pharma can save significant time: Faster technology transfers, faster regulatory submissions and efficient scale-up to commercial readiness.
1. Increased Tech Transfers
Transferring technology is one of the most challenging and longest running operations in pharmaceutical manufacturing.
In-house transfers might take 18 to 30 months and cost millions.
Industry data is even more disturbing, indicating that almost half of tech transfers have quality issues that lead to extra delays in development or scale-up. Collaborating with a specialised CDMO pharma provider can go a long way to eliminate wasted time from inefficiencies.
Are CDMO pharma partners better in tech transfer? Why?
Well-perfected protocols: Established CDMOs have standardised transfer procedures that have been honed over dozens, if not hundreds, of successful transfers
Cross functional teams: . Dedicated project managers collaborate with R&D scientists, process engineers and QA teams to get all the moving aspects in alignment early.
Proactive communication – sharing information proactively such as batch records, historical deviations and troubleshooting logs can stop the CDMO from doing the same work or making the same mistakes twice.
Built-in flexibility: If a production run goes wrong or a site needs to be changed, a competent CDMO pharma provider will use data that already exists to make up for lost time and avoid mistakes that have been made in the past.
The systematic and team approach helps to identify potential problems before they become downstream delays.
2. Expedited Regulatory Submissions
Another waste of time frequently spent is navigating the thicket of drug legislation. INDs, NDAs and other regulatory submissions involve huge amounts of data, thorough documentation and adherence to ever-changing regulatory standards.
Missing information or lack of compliance can lead to lengthy review delays, additional submission cycles, and unexpected delays in development timelines.
Partnering with a CDMO pharma provider that has in-house regulatory affairs (RA) expertise can make a meaningful difference.
CDMO pharma partners who focus in this space adopt a different strategy, with regulatory support being a core operating function, not an afterthought:
- RA teams are integrated into development and manufacturing processes.
- Experts work together from development to submission
- Submissions aligned with optimal regulatory methods to keep project on fast track
- CDMOs often additionally assign one RA point of contact throughout the duration of the product lifetime, to guarantee continuity and avoid any gaps in hand-offs.
And an informed RA staff knows what the regulators want to see:
- They produce high quality CMC sections, validation reports and technical data
- All submissions are FDA/EMA compliant Less back & forth, less regulatory questions
- They proactively manage deadlines and collaborate cross-functionally with analytical, clinical and manufacturing teams to meet timelines for submissions
- For operational leaders, that kind of foresight means fewer surprises, easier approvals and a development pipeline that runs with purpose.
3. Accelerated Scale-Up and Commercialisation
This is a big leap from gram scale or pilot batches to full commercial production, and without the right equipment, capacity and technical know-how, it could create a bottleneck.
The typical delays we see here include engineering problems, re-optimizing reaction processes at larger volumes or limited access to industrial facilities.
This is where a CDMO pharma partner can support. These partners shorten the trip to commercial scale manufacturing and offer end-to-end scale-up support along with built-in infrastructure, making the process far more predictable.
This ‘scale-up without transfer’ notion bypasses the usual delays of hand-off. For example, if a pharmaceutical successfully makes it through Phase 3, production may easily be ramped up to launch size numbers without waiting months for a new facility to be brought on line.
The CDMO’s deep process engineering expertise provides further time savings as well:
R&D and engineering teams (usually hundreds of people) optimise reactions at scale
Heat transfer, mixing behaviour and purifying yield are considered preliminarily.
Consistent purity, yields and cycle times with scale-up methods even at 10x or 100x batch size
That implies commercial manufacturing starts not with trial and error, but ready to operate, cutting down on lost time troubleshooting and retracing.
One of the big pluses is the easy availability of huge scale capability. When a drug becomes approved and market demand explodes a well-equipped CDMO can:
- Do not defer levels of supply production
- Meet worldwide demand from day one
- Ensure commercial supply chain flows smoothly
This means patients get therapy sooner, and pharmaceutical companies get a timely competitive advantage.”
Neuland Labs – The Right Pharma CDMO Partner
All of the above examples show how a CDMO cooperation brings the operational focus and skill set to keep projects on schedule. Neuland Labs is one such case.
Neuland offers specialized CDMO pharma support through the development lifecycle, including end-to-end API development from pre-IND to commercial production.
Neuland’s reactor capacity is 1.17+ million litres and has 360+ R&D professionals to scale complex projects without bottlenecks.
CDMO pharma like Neuland Labs is one such example that removes inefficiencies at every phase, integrating scientific depth with huge scale infrastructure. Faster technology transfers, more efficient regulatory applications and a faster road to commercial readiness.
FAQ (Frequently Asked Questions)
Why is tech transfer a challenge in pharma?
The transfer of technology is typically delayed because of missing paper work, noncompatible equipment, or lack of coordination between development and manufacture. In the absence of protocols and experience, companies can encounter delays, rework and quality issues that push back production schedules.
How pharma partners accelerate drug approvals via CDMO?
You have regulatory experts embedded into the CDMO pharma partner from day one, ensuring all data and documents are ready for submission. This pro-active support helps mitigate review delays and streamline the road to clinical trials or market launch.
Why is it so hard to scale-up pharma?
However, scaling up from laboratory to commercial scale has numerous intricate variables such as process consistency, equipment limits, batch size, etc. Such changes can sometimes lead to delays, reduced yields or costly plant resets without proper support.
Can a CDMO Pharma partner offer development and commercial supply?
Yes. CDMO pharma vendors like as Neuland Labs offer end-to-end support including process development, scale-up, validation and full-volume API manufacture. That decreases the number of vendors you need, and it reduces the time you lose in phase shift.
